Floatz logo

ZELUVALIMAB

Kirsten Rat Sarcoma (KRAS) pG12C Mutation

Amgenmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Kirsten Rat Sarcoma (KRAS) pG12C Mutation cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Amgen
Phase 1CC
Atezolizumab
Amgen
Phase 1CC
Docetaxel
Amgen
Phase 1CC
Eloxatin
Amgen
Phase 1CC
Sotorasib
Amgen
Phase 1CC

View all 19 →

Same molecule, other indications

ZELUVALIMAB is also rated in:

glioblastomaDormant
CC
Indicative ·
43 / 100
View asset →
cancerDormant
CC
Indicative ·
42 / 100
View asset →
metastatic prostate carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →